ASCO 2022: Endocrine sensitivity test predicts survival benefit of dose-dense chemotherapy for patients with HR+ breast cancer
A new genomic test designed to measure endocrine sensitivity of estrogen receptor-positive breast cancer has…
Browsing: ASCO
ASCO 2022: Study offers guidance for future trials of adjuvant therapy for patients with early HR+/HER2- breast cancer
To fully evaluate hormone-blocking therapy following surgery for patients with early-stage high-risk HR+/HER2- breast cancer,…
ASCO 2022: Patient-facing screening tool could increase detection of individuals with inherited cancer risk
Nearly one million people in the United States are affected by Lynch syndrome – a…
ASCO 2022: Novel immunotherapy combination improved survival in patients with metastatic melanoma
Combination immunotherapy treatment with anti-PD-1 and anti-CTLA-4 checkpoint inhibitors has proven effective as a front-line option for many patients…
ASCO 2022: Targeting p53 pathway shows promise for patients with Merkel cell carcinoma
Merkel cell carcinoma (MCC) is a rare and aggressive form of skin cancer caused by…
ASCO 2022: Acupuncture improves chronic radiation-induced dry mouth for patients with head and neck cancer
Most head and neck cancer patients treated with radiation therapy develop long-term treatment-related dry mouth, or xerostomia,…
ASCO 2022: Open-label placebo treatment reduces cancer-related fatigue in patients with advanced cancers
Cancer-related fatigue (CRF) is the most common symptom in patients with cancer, and there are limited…
ASCO 2022: Follow-up data further support the superior efficacy of cabozantinib in patients with progressive differentiated thyroid cancer
To be presented at the American Society of Clinical Oncology’s (ASCO) Annual Meeting, 03 – 07 June…
ASCO GU 2022: Enfortumab vedotin is effective in patients with aggressive bladder cancer
Findings from a new study led by Yale Cancer Center researchers show enfortumab vedotin is effective in…
ASCO GU 2022: Biomarker may help predict survival in patients with bladder cancer
Long-term survival data from the first prospective, randomized biomarker validation trial in patients with muscle-invasive…